Full Papers
Elevated DAS28-ESR in patients with rheumatoid arthritis who have comorbid fibromyalgia is associated more with tender joint counts than with patient global assessment or swollen joint counts: implications for assessment of inflammatory activity
S. Kannayiram1, J. Schmukler2, T. Li3, N. Goodson4, A. Sridhar5, T. Pincus6
- John H. Stroger, Jr. Hospital of Cook County, Internal Medicine, Chicago, IL, USA.
- Division of Rheumatology, Department of Medicine, Rush University School of Medicine, Chicago, IL, USA.
- Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University, Washington, DC, USA.
- University Hospital Aintree, Rheumatology, Liverpool, UK.
- Mercy Catholic Medical Center, Darby, PA, USA.
- Division of Rheumatology, Department of Medicine, Rush University School of Medicine, Chicago, IL, USA. tedpincus@gmail.com
CER17227
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 38525998 [PubMed]
Received: 23/10/2023
Accepted : 15/01/2024
In Press: 22/03/2024
Abstract
OBJECTIVES:
More than 20% of rheumatoid arthritis (RA) patients have comorbid fibromyalgia (FM+), which may elevate DAS28-ESR (disease activity score 28-erythrocyte sedimentation rate) and other indices, resulting in challenges to assess inflammatory disease activity. Although several reports indicate that elevated patient global assessment (PATGL) may elevate DAS28 in the absence of inflammatory activity, less information is available concerning the other three components, tender joint count (TJC), swollen joint count (SJC), and erythrocyte sedimentation rate (ESR), to possibly elevate DAS28 in FM+ vs. FM- RA patients.
METHODS:
A PubMed search identified 14 reports which presented comparisons of DAS28-ESR and its four components in RA FM+ vs. FM- groups. Median DAS28, component arithmetic differences, pooled effect sizes and 95% confidence intervals were analysed in the FM+ vs. FM- groups.
RESULTS:
In FM+ vs. FM- groups, median DAS28 was 5.3 vs. 4.2, SJC 4.0 vs. 3.0, TJC 13.2 vs. 5.3, PATGL 61.6 vs. 39.9, ESR 26.3 vs. 26.5. DAS28-ESR was classified as “high” (>5.1) in 11/14 FM+ groups and “moderate” (3.2-5.1) in all 14 FM- groups. Effect sizes in FM+ vs. FM- groups for DAS28-ESR, SJC, TJC, PATGL, and ESR were large (≥0.8) in 10/14, 1/13, 12/13, 7/13, and 1/13 comparisons, respectively, and pooled effect sizes 0.84 (0.3, 1.4), 0.33 (-0.4, 1.0), 1.27 (0.01, 2.5), 0.91 (-0.6, 2.4), and 0.07 (-0.6, 0.7), respectively.
CONCLUSIONS:
DAS28-ESR is elevated significantly in FM+ vs. FM- RA patients; pooled effect sizes were highest for TJC, followed by PATGL, SJC and ESR. The findings appear relevant to response and remission criteria, treat-to-target, and general management of RA.
